BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28928856)

  • 1. The Putative Role of
    Semczuk A; Gogacz M; Semczuk-Sikora A; Jóźwik M; Rechberger T
    J Cancer; 2017; 8(14):2684-2691. PubMed ID: 28928856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
    Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
    Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.
    Sallum LF; Sarian LO; Lucci De Angelo Andrade L; Vassallo J; Soares FA; Pinto GA; Ferreira PA; Derchain S
    J Gynecol Oncol; 2013 Apr; 24(2):167-76. PubMed ID: 23653835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
    Giurgea LN; Ungureanu C; Mihailovici MS
    Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
    Li M; Qi SY; Wang Y; Feng SX; Zhang BZ; Wang R
    Arch Gynecol Obstet; 2005 Jun; 272(1):48-52. PubMed ID: 15682318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
    Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
    Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
    Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management.
    Ferrero A; Strada I; Di Marcoberardino B; Maccarini LR; Pozzati F; Rossi M; Biglia N; De Iaco P
    Int J Gynecol Cancer; 2012 Sep; 22(7):1158-62. PubMed ID: 22801031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
    Gursan N; Sipal S; Calik M; Gundogdu C
    Eurasian J Med; 2009 Apr; 41(1):10-4. PubMed ID: 25610057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components.
    Timor-Tritsch IE; Foley CE; Brandon C; Yoon E; Ciaffarrano J; Monteagudo A; Mittal K; Boyd L
    Ultrasound Obstet Gynecol; 2019 Sep; 54(3):395-402. PubMed ID: 30950132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
    Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
    Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
    Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
    J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.